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Background: Over the past years knowledge about benefits of physical activity after cancer is evolving from
randomized exercise intervention trials. However, it has been argued that results may be biased by selective
participation. Therefore, we investigated factors influencing participation in a randomized exercise intervention trial
for breast cancer patients.
Methods: Non-metastatic breast cancer patients were systematically screened for a randomized exercise intervention
trial on cancer-related fatigue. Participants and nonparticipants were compared concerning sociodemographic
characteristics (age, marital status, living status, travel time to the training facility), clinical data (body-mass-index,
tumor stage, tumor size and lymph node status, comorbidities, chemotherapy), fatigue, and physical activity.
Reasons for participation or declination were recorded.
Results: 117 patients (52 participants, 65 nonparticipants) were evaluable for analysis. Multiple regression analyses
revealed significantly higher odds to decline participation among patients with longer travel time (p = 0.0012),
living alone (p = 0.039), with more comorbidities (0.031), previous chemotherapy (p = 0.0066), of age ≥ 70 years
(p = 0.025), or being free of fatigue (p = 0.0007). No associations were found with BMI or physical activity. By far
the most frequently reported reason for declination of participation was too long commuting time to the
training facility.
Conclusions: Willingness of breast cancer patients to participate in a randomized exercise intervention study
differed by sociodemographic factors and health status. Neither current physical activity level nor BMI appeared
to be selective for participation. Reduction of personal inconveniences and time effort, e.g. by decentralized
training facilities or flexible training schedules, seem most promising for enhancing participation in exercise
intervention trials.
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In recent years an increasing number of studies have
been published, evaluating the role of physical activity
during or after cancer treatment. It has been shown that
structured exercise training can reduce adverse effects in
cancer patients like cancer-related fatigue (CRF) [1-3],
improve quality of life [4] and positively impact cardiore-
spiratory fitness [5]. Most of the findings are based on
clinical studies with small numbers of subjects or pa-
tients, and there is an ongoing debate whether those pa-
tients willing to be randomized to a demanding exercise
program might be highly selective [6,7]. Clinical trials
are essential for research and randomized controlled
studies are considered the gold standard to evaluate new
therapies and determine efficacy or effectiveness of in-
terventions [8]. However, only 3-5% of all cancer pa-
tients in Great Britain and the US are included in
randomized controlled studies [9]. These low rates result
from strict study protocols together with patient- and
physician related factors, e.g. time constraints or influ-
ence on the relationship between physician and patient.
Moreover, it has been shown that the process of recruit-
ment itself is very selective and often threatens the
generalizability [10]. Data from clinical cancer trials
(mostly drug studies) suggest that age [11,12], tumor
stage [13,14], lymph node involvement [12], comorbidi-
ties [12], and travel distance [15,16] play an important
role in the acceptance or non-acceptance in study par-
ticipation. De Jong et al. [17] determined differences be-
tween participants and nonparticipants of an exercise
trial for patients with rheumatoid arthritis. They con-
cluded that nonparticipants were older, mainly males, suf-
fered for a longer duration from their disease and had a
lower level of education. To our knowledge, the determi-
nants of participation of cancer patients in exercise inter-
vention trials have not yet been systematically investigated
in this extent. It is important to explore these determi-
nants to improve participation rates in further trials.
Therefore aim of the present study was to investigate
factors that explain participation and nonparticipation in
an exercise intervention trial for breast cancer patients
undergoing adjuvant radiotherapy. This study focuses on
demographic, personal and clinical factors associated
with participation, as well as patient motivation.
Methods
Study design
The present BEST-Participation-study was carried out
from July 2011 to December 2011 during the patient
screening for the BEST-study. The BEST-study (in German:
Bewegung und Entspannung für Brustkrebspatientinnen
unter Strahlentherapie, translation: exercise and relaxation
for breast cancer patients during radiotherapy) is a pro-
spective, randomized, controlled intervention trial for non-metastatic breast cancer patients undergoing adjuvant
radiotherapy. The BEST-study compared a 12-week resist-
ance intervention program during and after radiotherapy
with relaxation training in regard to cancer-related fatigue
perception [18,19]. The BEST-Participation-study was an
observational study embedded in the BEST-study, collect-
ing information on factors potentially influencing willing-
ness to participate in a randomized exercise-intervention
trial. The aims of the present analysis were (1) to determine
clinical and sociodemographic characteristics of partici-
pants and nonparticipants, and (2) to identify reasons for
participation or declination. Patients, who signed informed
consent for the BEST trial automatically took part in the
BEST-Participation-study and are referred to as participants
throughout this manuscript. Patients, who refused partici-
pation in the BEST-study but agreed to fill out the short
questionnaire for the BEST-Participation-study, are referred
to as nonparticipants.
Protocols of the BEST- and of the BEST-Participation-
study were approved by the Ethic Committee of the
University of Heidelberg and have been performed in
accordance with the ethical standards of the Declar-
ation of Helsinki. The BEST-study is registered at Clini-
calTrials.gov (NCT01468766).Study population
All participants were treated at the National Center for
Tumor Diseases Heidelberg (NCT) in cooperation with
the Department of Radiooncology of the University Med-
ical Centre in Heidelberg. Inclusion criteria were: female
breast cancer patients with UICC stage I-III, indication for
adjuvant radiotherapy, age ≥ 18 years, BMI ≥ 18 kg/m2,
written informed consent, ability to follow instructions.
Exclusion criteria were: acute infection, problems with
walking or standing, severe neurological dysfunction, se-
vere cardiovascular disease, severe pulmonary insuffi-
ciency, severe renal insufficiency, other malignancies
(except carcinoma in situ of skin or cervix), abuse of alco-
hol or drugs, regular participation in resistance or endur-
ance training. Breast cancer patients were recruited by a
physician who was responsible for the assessment of in-
clusion and exclusion criteria. Both nonparticipants and
participants had to fulfill these BEST-inclusion criteria.Study recruitment
Eligible patients were briefly informed about the exercise
trial at their first consultation for radiotherapy at the
outpatient clinic of the Department of Radiooncology of
the NCT. Interested patients were handed out an infor-
mation sheet. They were called a few days later to get
more comprehensive information.
Upon informed consent women were included in the
BEST-study as well as in the BEST-Participation-study. As
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(see below) at their baseline visit for the study entry.
Patients refusing participation were asked whether they
would be willing to provide some reasons for their declin-
ation and to complete a brief questionnaire either imme-
diately in the outpatient clinic or at home, returned by
mail. Written informed consent was obtained from both,
BEST participants and nonparticipants. For the recruit-
ment flow see Figure 1.
Data collection
Clinical data, including tumor size, lymph node status,
tumor stage, comorbidities, chemotherapy (yes/no), age,
BMI, were collected from the clinical information sys-
tem. Additional information, such as sociodemographic
data, fatigue, physical activity and motivational aspects
for exercise, was assessed by self-administered question-
naires. Patients were asked to specify marital status (mar-
ried/living with partner, separated, divorced, widowed,
single, not specified), living status (alone, with others) and
travel distance (up to 30 min, between 30 min and 1 h,
more than 1 h) to the training center. For a baseline as-
sessment of physical activity reflecting the last week prior
to inclusion we used the short version of the Freiburg
questionnaire of physical activity (FFKA) [20], a standard-
ized and validated instrument. FFKA focuses on everyday
activity with low to medium exertion in addition to exer-
cise activities. With 8 questions basal, recreational and
sportive activities are assessed. Cancer-related fatigue, the
primary endpoint of the BEST-study, was measured by the
multidimensional, 20-item Fatigue Assessment Question-
naire (FAQ) [21]. FAQ is a standardized and validated
questionnaire for self-assessment of the physical, cognitive
and affective dimensions of fatigue. In addition, using a
visual analogue scale (0 = not tired at all, 10 = totally
exhausted), patients were asked to rate the intensity of
current fatigue. Besides the continuous fatigue scores
(total physical, cognitive and affective fatigue) we alsoFigure 1 Recruitment flow.investigated a dichotomous variable using as cutpoint the
mean fatigue score of women age ≥ 60 years from the gen-
eral German population (FAQ point value for women
aged 14–39 years: 11,2; aged 40–59 years: 12,1; aged ≥
60 years) [22].To assess the motivation of patients to
participate in the BEST-study they could choose among
7 answers, in addition to provide their own free text.
Nonparticipants had the choice between 15 answers
and free text to explain why they decided against study
participation. Multiple answers were allowed.
If the questionnaires were not returned, patients were
reminded at least three times by phone. All questionnaires
and clinical information had to be completed prior to the
first radiotherapy.
Statistical analysis
Characteristics of participants and nonparticipants were
compared using Student’s t-test (metric data), Mann–
Whitney-U-test (ordinal data), or Chi2-test (categorical
data). To assess the associations between the character-
istics and nonparticipation, we performed multiple lo-
gistic regression analyses assessing following covariates
simultaneously in the model: age group, number of co-
morbidities, marital status, living status, travel distance,
BMI, previous chemotherapy, and fatigue. Due to high
collinearity tumor characteristics were investigated in
separate models without chemotherapy. The different
physical activity variables were also included in the
models, but none showed a significant association with
nonparticipation. Additional sensitivity analyses were
performed using smaller sets of covariates to check for
overfitting or spurious effects by related variables, but
there were no substantial changes in the results. Reasons
for participation or declination were analyzed descrip-
tively. P-values below 0.05 were considered as statisti-
cally significant. All analyses were performed using
PASW Statistics 19.0 or SAS 9.2 [SAS Institute Inc.,
Cary, USA].
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From July to December 2011 a total of 398 patients with
non-metastatic breast cancer were irradiated at the study
clinic. In this period 52 participants and 69 nonparticipants
were recruited (Figure 1). Due to missing data from 4 non-
participants the sample was restricted to 65 evaluable non-
participants. The remaining 277 patients were either not
eligible, received no information from the recruiting physi-
cians or were not interested in any study participation.
Thus, information for this BEST-Participation-study was
available for 30.4% of all breast cancer patients with adju-
vant radiotherapy during the study period.Characteristics of participants and non-participants
Sociodemographic characteristics are presented in
Table 1. The mean age did not differ statistically signifi-
cantly between participants and nonparticipants (p =
0.64). However, participants were more likely to be mid-
dle aged (age 40–70 years) whereas nonparticipants were
more likely to be younger or older (<40 years, ≥ 70 years)
(p = 0.02). Significant differences were also noted for liv-
ing status (p = 0.009) and travel distance (p = 0.02). Here,
the nonparticipants more commonly reported living
alone and had to spend more time to travel from their
home to the treatment center. There were no significant
differences with respect to marital status (p = 0.18).
Tumor size (p = 0.047), nodal status (p = 0.036) and
tumor stage (p = 0.043) were indicative for a locally more
advanced disease among nonparticipants. The number
of comorbidities tended to be higher in nonparticipants
(p = 0.066). Prior treatment with chemotherapy was some-
what more frequently reported by nonparticipants (p =
0.09). No difference between both groups was observed
for BMI (p = 0.14).
Participants and nonparticipants had comparable
current physical activity levels (p > .99) (see Table 2).
Only 34.6% of the participants and 33.8% of the nonpar-
ticipants were classified as “sufficiently active” according
to the criteria of Frey and Berg [23] (total score in the
FFKA of 30 or a score of 14 in sportive activities) prior
to starting radiotherapy. Compared to a healthy refer-
ence group [20] our entire study population was com-
parably active in day-to-day and recreational activities,
but less so with respect to exercise activities.
Neither total fatigue levels (p = 0.25) nor levels for the
subcategories physical, cognitive, and affective fatigue or
sleep problems differed significantly between the groups
(see Table 3). There was also no significant difference
between participants and nonparticipants with regard to
their fatigue levels the year before diagnosis, at the days
after surgery, or during chemotherapy (if applicable).
However, among nonparticipants significantly (p = 0.01)
more women were currently free of fatigue (i.e. withlevels below the mean fatigue level of the general refer-
ence population) than among participants.
Multiple logistic regression analyses (see Table 4) showed
significantly higher odds for nonparticipation among pa-
tients with higher age, higher number of comorbidities,
those living alone, having longer travel distances, having re-
ceived a chemotherapy, or those not feeling fatigued. Di-
vorced or separated women had lower odds to refuse
participation. BMI and physical activity were not associated
with participation.
Due to high collinearity, the variables tumor stage, tumor
size, and chemotherapy were not included jointly in a
model. Similar results were observed in the models with ei-
ther tumor stage or tumor size instead of chemotherapy,
with OR = 3.3 (1.2 – 9.3) for higher stage vs. lower stage,
and OR = 4.6 (1.4 – 15.1) for tumor sizes T2/3 vs. T1/Tis
(data not shown).
Reasons for participation or non-participation
When asked for their reasons for acceptance or declin-
ation of the study the five most frequently stated motiv-
ational aspects of BEST participants were: “I hope to
reduce fatigue and improve quality of life” (65.4%), “I want
to contribute to scientific progress” (65.4%), “I hope for
positive effects on my cancer prognosis” (59.6%), “I want
to cope with cancer” (59.6%), “I hope for better fitness and
health” (57.7%) (see Table 5). Nonparticipants most often
named “Journey too far/difficulties to reach training cen-
ter” (70.8%) as reason for their declination. “Time con-
flicts” (23.1%) and “Twice a week training is too much”
(13.8%) were followed by “Health problems” and “I do not
want to participate in relaxation” (both 12.3%) (see
Table 6).
Discussion
The present study showed that willingness of breast cancer
patients to participate in a randomized exercise interven-
tion study was significantly influenced by age distribution,
comorbidities, living status, travel time to the training cen-
ter, cancer characteristics or treatment, and fatigue. No as-
sociations were observed with BMI and extent of current
physical activity.
Patient’s well-being often is negatively influenced by
cancer itself as well as by common cancer therapies. In-
tervention studies have revealed the importance of phys-
ical activity as an effective method in supportive therapy
[1,2,4,5].
In literature, generalizability of results from clinical tri-
als to the overall patient population has been questioned
[12,14,24]. Discrepancies between willingness in general
expressed by healthy persons to participate in a clinical
cancer trial versus actual participation rates in patient
populations have been addressed in the study from
Comis et al. 2003: In a survey healthy Americans were
Table 1 Sociodemographic and clinical characteristics of participants and nonparticipants
Total (n = 117) Participants (n = 52) Nonparticipants (n = 65) p-Value
Mean age (SD) 57.0 (11.3) 56.5 (9.3) 57.5 (12.7) 0.64
Age groups 0.02
<40 years 7 (6%) 1 (1.9%) 6 (9.2%)
40-49 years 24 (20.5%) 14 (26.9% ) 10 (15.4%)
50-59 years 37 (31.6%) 17 (32.7%) 20 (30.8%)
60-69 years 31 (26.5%) 17 (32.7%) 14 (21.5%)
≥70 years 18 (15.4%) 3 (5.8%) 15 (23.1%)
Marital status 0.18
Married/living with partner 78 (66.7%) 38 (73.1%) 40 (61.5%)
Separated 3 (2.6%) 2 (3.8%) 1 (1.5%)
Divorced 11 (9.4%) 6 (11.5%) 5 (7.7%)
Widowed 18 (15.4%) 5 (9.6%) 13 (20%)
Single 7 (6.0%) 1 (1.9%) 6 (9.2%)
Living status 0.01
Alone 32 (27.4%) 8 (15.4% ) 24 (36.9%)
With others 85 (72.6%) 44 (84.6%) 41 (63.1%)
Travel distance 0.02
Up to 30 minutes 30 (25.6% ) 18 (34.6%) 12 (18,5%)
Between 30 minutes and 1 h 67 (57.3%) 30 (57.7%) 37 (56.9%)
More than 1 h 20 (17.1%) 4 (7.7%) 16 (24.6%)
Mean BMI [kg/m2] (SD) 26.3 (4.5) 25.7 (4.7) 26.9 (4.4) 0.14
Tumor size 0.047
Tis 16 (13.7%) 8 (15.4%) 8 (12.3%)
T1 66 (56.4%) 34 (65.4%) 32 (49.2%)
T2 30 (25.6%) 9 (17.3%) 21 (32.3%)
T3 5 (4.3%) 1 (1.9%) 4 (6.2%)
Nodal status 0.04
Positive 34 (29.1%) 10 (19.2%) 24 (36.9%)
Negative 83 (70.9%) 42 (80.8%) 41 (63.1%)
Tumor stage (UICC) 0.04
0 15 (12.8%) 8 (15.4% ) 7 (10.8%)
1 55 (47.0%) 29 (55.8%) 26 (40.0%)
2 35 (29.9%) 11 (21.2%) 24 (36.9%)
3 12 (10.3%) 4 (7.7%) 8 (12.3%)
Number of comorbidities 0.07
0 48 (41.0%) 25 (48.1%) 23 (35.4%)
1 43 (36.8%) 20 (38.5%) 23 (35.4%)
2 14 (12.0%) 3 (5.8%) 11 (16.9%)
≥3 12 (10.3%) 4 (7.7%) 8 (12.3%)
Chemotherapy 0.09
yes 46 (39.3%) 16 (30.8%) 30 (46.2%)
no 71 (60.7%) 36 (69.2%) 35 (53.8%)
Fatigue
any 83 (70.9%) 43 (82.7%) 40 (61.5%) 0.01
none 34 (29.1%) 9 (17.3%) 25 (38.5%)
SD: Standard Deviation.
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Table 2 Physical activity levels of participants and nonparticipants (BEST-study) according to the short version of the
FFKA
Total (n = 117) Participants (n = 52) Nonparticipants (n = 65) p-Value
Total activity score* (SD) 27.9 (25.8) 28.2 (26.4) 27.6 (25.5) >0.99
Basal activities* (SD) 10.6 (11.4) 10.6 (11.3) 10.6 (11.6) 0.79
Recreational activities* (SD) 12.5 (12.4) 13.0 (12.1) 12.1 (12.8) 0.48
Sportive activities* (SD) 4.8 (11.9) 4.6 (13.2) 4.9 (10.8) 0.89
*MET x hours/week.
SD: Standard Deviation, MET: metabolic equivalent of task.
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cancer trial if they were faced with cancer diagnosis. 31%
indicated to be “very willing”, 51% “somewhat willing”,
9% “not very willing” and 6% “not willing at all” [25].
This is in clear contrast to the finding that only 3 to 5%
of all cancer patients in Great Britain and the US partici-
pate in clinical trials [9]. Reasons may be that no appro-
priate study was open, patients were not informed about
ongoing studies or were ineligible, or patients were not
willing to participate. In the BEST-study 13.1% of the
target population could be enrolled during the recruit-
ment period (from July to December 2011). In conse-
quence it is assumed that participation in intervention
studies is highly selective.
In the present study, travel distance was a major factor
reducing study participation: Participation in the inter-
vention trial required the acceptance to travel twice a
week to the treatment center and to spend extra time for
the training. The present study shows that patients who
needed significantly less time to reach the training centre
were more likely to agree. Furthermore, 70.8% of the non-
participants named “journey too far/difficulties to reach
training centre” as an important reason for refusing to
participate. Long travel distances and limited transporta-
tion capabilities are held responsible for less utilization of
cancer treatment [26]. In line, studies from gynecological
cancer types reported that travel distance and study par-
ticipation are reciprocally related to each other [15].
Participants of the BEST-study represented the age
group between 40 to 69 years very well. However, pa-
tients aged younger than 40 years or older than 69 years
only accounted for 7.7% of the trial participants whereas
32.2% of the nonparticipants were classified in these
groups. Higher age was even significantly associated withTable 3 Fatigue levels of participants and nonparticipants (BE
Total (n = 117) Participan
Total fatigue (SD) 22.1 (13.8) 23.5 (11.1)
Physical fatigue (SD) 12.4 (8.9) 12.8 (7.7)
Cognitive fatigue (SD) 2.9 (2.6) 3.2 (2.2)
Affective fatigue (SD) 5.4 (4.0) 6.1 (3.7)
Sleep problems 1.4 (1.1) 1.5 (1.0)
SD: Standard Deviation.nonparticipation when adjusting for other factors such
as comorbidities. Our results strengthen previous studies
observing that especially older patients are underrepre-
sented in clinical trials, although they comprise about
one third of newly diagnosed breast cancer patients
[12,27,28]. A detailed explanation for the selected repre-
sentation of younger patients cannot be determined due
to the small size of this age group.
In the BEST-Participation-study among nonpartici-
pants a larger proportion reported living alone. Partici-
pants tended to be more often married, while widowed
or single women were more frequent among nonpartici-
pants, but differences were not statistically significant.
Our data suggest that social and perhaps logistical sup-
port is an important component when considering par-
ticipation in a rather time-consuming clinical exercise
trial. These data are in line with Elting et al. [12] who
compared social factors of participants and nonpartici-
pants with different cancer types. However, two other
studies could not find such associations [17,29].
Comparable to Elting et al. who observed higher per-
centages of comorbidities in nonparticipants [12], the
present study revealed a statistical association between
more comorbidities and nonparticipation when adjusting
for other characteristics. Participants had smaller tumor
sizes, lower tumor stages and less frequently positive
lymph nodes than nonparticipants. Potentially, physical
activity intervention trials are selective for patients with
less advanced and rather local disease.
Importantly, nonparticipants and participants did not
differ in their physical activity level and both groups
showed a predominantly sedentary lifestyle. Thus, the
present study suggests that exercise intervention studies
are not selectively addressing more active patients. LikewiseST-study) according to FAQ
ts (n = 52) Nonparticipants (n = 65) p-Value
20.9 (15.7) 0.25
12.1 (9.8) 0.43
2.7 (2.8) 0.14
4.9 (4.2) 0.06
1.3 (1.1) 0.24
Table 4 Multiple logistic regression model assessing the
odds for nonparticipation
Covariates OR (95% CI) p
Age groups 0.025
<40 years 6.5 (0.5 – 86.4))
40-49 years Ref.
50-59 years 3.7 (0.9 – 15.8)
60-69 years 1.0 (0.2 – 5.7)
≥70 years 16.1 (1.7 – 150.4)
Number of comorbidities 0.031
0 Ref.
1 2.8 (0.8 – 10.0)
≥2 10.6 (1.8 – 62.1)
Marital status 0.047
Married/ living with partner Ref.
Separated/divorced 0.1 (0.02 – 0.9)
Widowed 0.2 (0.03 – 1.3)
Single 14.3 (0.4 – 581.8)
Living status 0.039
With others Ref.
Alone 6.5 (1.1 – 38.3)
Travel distance 0.0012
Up to 30 minutes Ref.
Between 30 minutes and 1 h 12.3 (2.7 – 56.7)
More than 1 h 19.4 (3.4 – 110.8)
Body mass index 0.33
Normal Ref.
Overweight 2.2 (0.7 – 7.0)
Adipose 2.3 (0.5 – 10.1)
Chemotherapy 0.0066
No Ref.
Yes 5.3 (1.6 – 17.8)
Fatigue 0.0007
Any Ref.
None 12.7 (2.9 – 54.9)
OR: odds ratio; CI: confidence interval.
Bold numbers indicate statistically significant results at level 0.05.
Table 5 Motivations for study participation reported by
participants of the BEST-study
Participant’s motivations (n = 52)
I want to contribute to scientific progress, that future patients
benefit thereof
65.4%
I hope to reduce fatigue and improve quality of life 65.4%
I hope for positive effects on cancer prognosis 59.6%
I want to cope with cancer 59.6%
I hope for better fitness and health 57.7%
Social contact to other persons concerned 38.5%
Recommendation of the physician 28.8%
Other reasons 7.7%
Table 6 Reasons for declination of study participation
given by nonparticipants of the BEST-study
Nonparticipant’s reasons (n = 65)
Journey too far/difficulties to reach training centre 70.8%
Time conflicts 23.1%
Twice a week training is too much 13.8%
Health problems 12.3%
I do not want to participate in relaxation 12.3%
Dislike of randomization 10.8%
Additional time for questionnaires and measurements
is too much
9.2%
Pain 9.2%
Resistance training too exhausting 7.7%
Too tired or not motivated enough 6.2%
I can’t be bothered 3.1%
Doubts about meaningfulness of the study 1.5%
Doubts about benefit of the training 1.5%
Investigation too burdensome/ inconvenient 1.5%
1 h training/session is too much 1.5%
Prefer not to give reasons 1.5%
Other reasons 15.4%
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on participation in an exercise trial. As the BEST-study fo-
cuses on interventions against fatigue, it is not surprising
that patients who did not feel fatigued at all were more
likely to refuse study participation.
In the literature two main theories are discussed to ex-
plain motivation of participants to participate in clinical
trials: Altruistic motives as well as self-interested argu-
ments. Jenkins and Fallowfield [30] found that a major
argument for participation in clinical trials is the desire
to help future patients who are confronted with cancerdiagnosis. In contrast to these results Truong et al. [31]
showed that altruism is not the primary reason for accept-
ing participation. Catt et al. [32] also discussed personal
benefits to be responsible for acceptance or non-acceptance
of trial inclusion. In the Best-Participation-study we ob-
served both of these motivations. “I hope to reduce fatigue
and improve quality of life” and “I want to contribute to sci-
entific progress, that future patients benefit thereof” were
the two most frequent statements. Thus, the feeling to in-
fluence cancer prognosis and to positively impact the own
health status seems both to be important to patients.
Declination of study participation in the BEST-study
was largely attributable to the distance to get to the
training centre or to difficulties related to commuting.
Previous studies also showed that distance and limited
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ticipation [33,34]. In a review Ross et al. [35] concluded
that long travel distances associated with higher costs led
to a declination of study participation and higher dropout
rates. “Date difficulties”, “Twice a week training is too
much” and “Additional time for questionnaires and mea-
surements is too much” can be summarized as additional
logistical constraints that may be important in line with
findings from other studies [34,36].
Our study had several strengths: By including only
patients who were classified to be eligible through the
BEST-study protocol and were offered participation from
physicians we were able to investigate patient-related fac-
tors in relation to participation and nonparticipation. In
contrast, most of the previous studies investigating these
differences used retrospective designs where recruitment
procedures and criteria were not fully comparable be-
tween participants and nonparticipants. Furthermore we
collected additional information like fatigue status or
physical activity level which are important variables in the
emerging field of exercise interventions among cancer pa-
tients. A limitation of our BEST-Participation-study is,
that as most of the clinical studies, we also cannot report
on the exact percentage of contacted patients with respect
to the entire target population. Due to organizational diffi-
culties in the recruitment process, such as short-term al-
terations of the medical staff or time constraints of the
physicians, not all patients were informed about the
BEST-study, and among patients not willing to partici-
pate in BEST, not all were asked to complete the ques-
tionnaires of the BEST-Participation-study. Beyond that
a certain proportion of the target population decided
against any study participation, so that only 30.4% of all
patients with breast cancer stage I-III responded to the
BEST-Participation-study, either with participation or
non-participation in the BEST-study. Further research is
necessary to verify these aspects in detail.
Conclusions
Our study suggest that breast cancer patients are less
willing or able to participate in a randomized resistance
exercise trial if they live alone, have a long travel dis-
tance, a worse cancer prognosis, had a recent chemo-
therapy, are affected by fatigue, are above age 70 or have
more comorbidities. However, there seemed to be no se-
lection by current physical activity level or BMI. By far
the most frequently reported reason for declination of
participation was too long commuting time to the train-
ing facility. Our results might help to improve participa-
tion by adapting recruitment procedures in future
exercise intervention studies appropriately.
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